West China Journal of Stomatology ›› 2021, Vol. 39 ›› Issue (6): 617-623.doi: 10.7518/hxkq.2021.06.001

    Next Articles

Expanding the concept of patient-derived xenografts cohorts in head and neck cancer: current and future perspectives

Zhang Zhiyuan(), Sun Shuyang   

  1. Dept. of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology, Shanghai 200011, China
  • Received:2021-06-09 Revised:2021-07-27 Online:2021-12-01 Published:2021-12-03
  • Contact: Zhang Zhiyuan E-mail:zhzhy0502@163.com
  • Supported by:
    The National Key Research and Development Program of China(2017YFC0908500);Key Program of National Natural Science Foundation of China(82030085)


Head and neck cancer is the seventh common cancer in the world, and various existing treatment strategies provide modest benefit for most patients with head and neck cancer. Meanwhile, therapeutic strategies lacking molecular typing significantly hinder the development of individualized treatment for head and neck cancer. In recent years, connected by preclinical models, the novel ideal has gradually reached a consensus in terms of facilitating inter-transformation of clinical problems and basic achievements. As a bridge between basic research and clinical transformation, patient-derived xenografts (PDX) models precisely replicate genetic characteristics and tumor evolution, which are displaying great vitality in elucidating the mechanism of tumorigenesis and progression. Moreover, cohorts composed of several PDX models highlight the unique advantages of mice for drug screening and biomarker analysis for patients. This ideal preclinical model explores potential treatment strategies suited the ethical standards as much as possible for patients.

Key words: patient-derived xenografts, head and neck cancer, heterogeneity, drug screening

CLC Number: